Chemical compounds
AssigneeAstraZeneca AB
InventorsBernard Christophe BARLAAM, Daniel Hillebrand O'DONOVAN, Samantha Jayne HUGHES, Thomas Andrew MOSS, Johannes Wilhelmus Maria NISSINK, James Stewart SCOTT, Bin YANG
Life of this patent
Estimating the term…
Abstract
The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.
Claims14
A compound of Formula (I):
- wherein:
- A is CR2 or N;
- G is CR3 or N;
- D is CR4 or N;
- E is CR5 or N;
- Q is O, NH or NMe;
- R1 is CH2F, CHF2 or CF3;
- R2 is H, F, Cl, Me, CN, OMe or OEt;
- R3 is H or F;
- R4 is H, F, CN or OMe;
- R5 is H or F;
- R6 is H, Me, CH2F, CHF2 or CF3;
- R7 is H or Me;
- R8 is C1-3 alkyl, CH2F, CHF2, CF3 or C3-4 cycloalkyl;
- R9 is Me, F or CH2F;
- R10 is Me, F, CH2F, CHF2, CF3, CH2OMe or CH2OH;
- R11 is H or F;
- or
- R10 and R11 taken together with the carbon atom to which they are attached form a cyclopropyl ring or an oxetane ring;
- R12 is independently selected from F or Me;
- R13 is H or F;
- and
- a is 0, 1 or 2;
- or a pharmaceutically acceptable salt thereof.
8-9. (canceled)
A method for the prevention or treatment of cancer in a warm-blooded animal, in need of such treatment which comprises administering to said animal an effective amount of a compound of the Formula (I) or (IA) or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-7 or 13.
11-12. (canceled)
Dependencies are inferred from the claim text.